March 2016 News Recap

Researchers have determined that donor age has a stronger, nonlinear impact on OS vs donor type in allogeneic HCT using posttransplant cyclophosphamide for GVHD prophylaxis, with donor type becoming increasingly relevant in older donors.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.